Published in Neoplasia on September 01, 2015
Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget (2017) 0.76
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. Oncotarget (2016) 0.75
Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol (2007) 11.48
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol (1996) 7.64
SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell (1998) 6.62
SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem (2000) 4.96
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet (2004) 4.95
The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol (2010) 4.72
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell (2002) 4.09
PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene (1996) 3.73
The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem (2001) 3.64
The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature (2009) 3.62
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol (2002) 3.25
SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol Cell (2002) 2.93
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A (2002) 2.85
Structure determination of the small ubiquitin-related modifier SUMO-1. J Mol Biol (1998) 2.66
Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood (2007) 2.65
SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci (1999) 2.46
Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem (2005) 2.44
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 2.36
Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J Biol Chem (2000) 2.34
Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. J Cell Biol (1998) 2.29
The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J Biol Chem (1999) 2.21
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Retracted SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell (2000) 2.12
The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc Natl Acad Sci U S A (1998) 2.05
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol (1997) 2.04
UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics (1996) 2.00
Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene (2004) 1.95
A proteomic study of SUMO-2 target proteins. J Biol Chem (2004) 1.92
Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem (2003) 1.88
SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem (2003) 1.82
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J Biol Chem (2007) 1.61
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat Struct Mol Biol (2005) 1.58
Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat Cell Biol (2006) 1.52
Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry (2010) 1.38
SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol (2008) 1.32
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc Natl Acad Sci U S A (2001) 1.26
Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1. Biochem J (2005) 1.25
Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood (2004) 1.24
Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am J Physiol Endocrinol Metab (2002) 1.23
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood (2006) 1.22
Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci U S A (2003) 1.20
SUMOylation regulates nuclear localization of Krüppel-like factor 5. J Biol Chem (2008) 1.18
Nucleolar protein B23/nucleophosmin regulates the vertebrate SUMO pathway through SENP3 and SENP5 proteases. J Cell Biol (2008) 1.18
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood (2009) 1.18
Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell (2014) 1.10
SUMO-1 controls the protein stability and the biological function of phosducin. J Biol Chem (2006) 1.08
Caspase-8 sumoylation is associated with nuclear localization. Oncogene (2005) 1.06
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood (2007) 1.05
Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem (2003) 1.01
Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res (2013) 0.99
Detection of proteins sumoylated in vivo and in vitro. Methods Mol Biol (2009) 0.98
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood (2009) 0.98
Broad spectrum identification of SUMO substrates in melanoma cells. Proteomics (2007) 0.98
Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. Br J Haematol (2002) 0.97
SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development. EMBO Rep (2014) 0.95
SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res (2004) 0.92
SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. Cancer Res (2013) 0.90
De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells. Oncotarget (2014) 0.85
Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins. J Proteome Res (2014) 0.84
Pax8 protein stability is controlled by sumoylation. J Mol Endocrinol (2008) 0.84
Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia (2013) 0.83
The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget (2014) 0.82
Involvement of activated SUMO-2 conjugation in cardiomyopathy. Biochim Biophys Acta (2015) 0.77
The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma. Mol Cancer (2015) 0.77
SUMO2 overexpression enhances the generation and function of interleukin-17-producing CD8⁺ T cells in mice. Cell Signal (2015) 0.76
SUMO modification regulates the protein stability of NDRG1. Biochem Biophys Res Commun (2015) 0.75
The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget (2014) 0.82
Genotoxicity of tri- and hexavalent chromium compounds in vivo and their modes of action on DNA damage in vitro. PLoS One (2014) 0.79
Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget (2017) 0.76